Selenium cytotoxicity in cancer

Basic and Clinical Pharmacology and Toxicology

Volumn 114, Issue 5, 2014, Pages 377-386

  Wallenberg, Marita ^a   Misra, Sougat ^a   Björnstedt, Mikael ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXYESTRADIOL; AURANOFIN; BUTHIONINE SULFOXIMINE; CASPASE; CYTOSTATIC AGENT; DOXORUBICIN; ERYTHROSELENIUM BETA; GLUTAREDOXIN; GLUTATHIONE; METHYLSELENINIC ACID; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; MITOCHONDRIAL PROTEIN; MONOMETHYLSELENOL; PROTEIN P53; S ADENOSYLMETHIONINE; SELENIDE; SELENITE; SELENIUM; SELENIUM DERIVATIVE; SELENOCYSTEINE; SELENODIGLUTATHIONE; SELENOMETHIONINE; SELENOMETHYLSELENOCYSTEINE; SELENOPROTEIN P; SODIUM SELENITE; THIOREDOXIN; THIOREDOXIN REDUCTASE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL; CELL DEATH; CELL PROLIFERATION; CYTOTOXICITY; DNA DAMAGE; DNA FRAGMENTATION; DRUG MECHANISM; DRUG METABOLISM; ENDOPLASMIC RETICULUM STRESS; HUMAN; INTRACELLULAR SIGNALING; NONHUMAN; ONCOGENE; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; SHORT SURVEY; TUMOR CELL; UNFOLDED PROTEIN RESPONSE; ANIMAL; CELL SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DEATH; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; OXIDATION-REDUCTION; SELENIUM; SELENIUM COMPOUNDS;

EID: 84897962087     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/bcpt.12207     Document Type: Short Survey

References (76)

1. Berzelius JJ. Undersökning af en ny Mineral-kropp, funnen i de orenare sorterna af det i Falun tillverkade svaflet, in Afhandlingar i fysik, kemi och mineralogi. 1818, Stockholm. p. 42-144.
2. Bagnall KW. Selenium, tellurium and polonium. In: Bailar JC, Emeleus HJ, Nyholm R, Trotman-Dickenson AF (eds). Comprehensive Inorganic Chemistry. Pergamon Press, Oxford, 1973;935-1008.
3. Stadtman T. Some selenium-dependent biochemical processes. Adv Enzymol 1979;48:1-28.
4. Huber RE, Criddle RS. Comparison of the chemical properties of selenocysteine and selenocystine with their sulfur analogs. Arch Biochem Biophys 1967;122:164-73.
5. Papp LV, Lu J, Holmgren A, Khanna KK. From selenium to selenoproteins: synthesis, identity, and their role in human health. Antioxid Redox Signal 2007;9:775-806.
6. Selenius M, Rundlof AK, Olm E, Fernandes AP, Bjornstedt M. Selenium and the selenoprotein thioredoxin reductase in the prevention, treatment and diagnostics of cancer. Antioxid Redox Signal 2010;12:867-80.
7. Björnstedt M, Kumar S, Holmgren A. Selenodiglutathione is a highly efficient oxidant of reduced thioredoxin and a substrate for mammalian thioredoxin reductase. J Biol Chem 1992;267:8030-4.
8. Kumar S, Björnstedt M, Holmgren A. Selenite is a substrate for calf thymus thioredoxin reductase and thioredoxin and elicits a large non-stoichiometric oxidation of NADPH in the presence of oxygen. Eur J Biochem 1992;207:435-9.
9. Wallenberg M, Olm E, Hebert C, Björnstedt M, Fernandes AP. Selenium compounds are substrates for glutaredoxins: a novel pathway for selenium metabolism and a potential mechanism for selenium mediated cytotoxicity. Biochem J 2010;429:85-93.
10. Fernandes AP, Wallenberg M, Gandin V, Misra S, Tisato F, Marzano C et al. Methylselenol formed by spontaneous methylation of selenide is a superior selenium substrate to the thioredoxin and glutaredoxin systems. PLoS One 2012;7:e50727.
11. Björnstedt M, Kumar S, Björkhem L, Spyrou G, Holmgren A. Selenium and the thioredoxin and glutaredoxin systems. Biomed Environ Sci 1997;10:271-9.
12. Esaki N, Nakamura T, Tanaka H, Soda K. Selenocysteine lyase, a novel enzyme that specifically acts on selenocysteine. Mammalian distribution and purification and properties of pig liver enzyme. J Biol Chem 1982;257:4386-91.
13. Esaki N, Tanaka H, Uemura S, Suzuki T, Soda K. Catalytic action of L-methionine.gamma.-lyase on selenomethionine and selenols. Biochemistry 1979;18:407-10.
14. Ohta Y, Suzuki KT. Methylation and demethylation of intermediates selenide and methylselenol in the metabolism of selenium. Toxicol Appl Pharmacol 2008;226:169-77.
15. Gammelgaard B, Bendahl L. Selenium speciation in human urine samples by LC- and CE-ICP-MS-separation and identification of selenosugars. J Anal At Spectrom 2004;19:135-42.
16. Jackson MI, Lunøe K, Gabel-Jensen C, Gammelgaard B, Combs Jr GF. Metabolism of selenite to selenosugar and trimethylselenonium in vivo: tissue dependency and requirement for S-adenosylmethionine-dependent methylation. J Nutr Biochem 2013;24:2023-30.
17. Oberley TD, Oberley LW. Antioxidant enzyme levels in cancer. Histol Histopathol 1997;12:525-35.
18. Benassi B, Fanciulli M, Fiorentino F, Porrello A, Chiorino G, Loda M et al. c-Myc Phosphorylation Is Required for Cellular Response to Oxidative Stress. Mol Cell 2006;21:509-19.
19. Zhang W, Yan S, Liu M, Zhang G, Yang S, He S et al. β-Catenin/TCF pathway plays a vital role in selenium induced-growth inhibition and apoptosis in esophageal squamous cell carcinoma (ESCC) cells. Cancer Lett 2010;296:113-22.
20. Brandes N, Schmitt S, Jakob U. Thiol-based redox switches in eukaryotic proteins. Antioxid Redox Signal 2009;11:997-1014.
21. Pantano C, Reynaert NL, van der Vliet A, Janssen-Heininger YM. Redox-sensitive kinases of the nuclear factor-kappaB signaling pathway. Antioxid Redox Signal 2006;8:1791-806.
22. Matthews JR, Wakasugi N, Virelizier JL, Yodoi J, Hay RT. Thioredoxin regulates the DNA binding activity of NF-kappa B by reduction of a disulphide bond involving cysteine 62. Nucleic Acids Res 1992;20:3821-30.
23. Bogeski I, Kappl R, Kummerow C, Gulaboski R, Hoth M, Niemeyer BA. Redox regulation of calcium ion channels: chemical and physiological aspects. Cell Calcium 2011;50:407-23.
24. Sheftel A, Stehling O, Lill R. Iron-sulfur proteins in health and disease. Trends Endocrinol Metab 2010;21:302-14.
25. Lill R, Hoffmann B, Molik S, Pierik AJ, Rietzschel N, Stehling O et al. The role of mitochondria in cellular iron-sulfur protein biogenesis and iron metabolism. Biochim Biophys Acta 2012;1823:1491-508.
26. Papp LV, Lu J, Striebel F, Kennedy D, Holmgren A, Khanna KK. The redox state of SECIS binding protein 2 controls its localization and selenocysteine incorporation function. Mol Cell Biol 2006;26:4895-910.
27. Painter EP. The chemistry and toxicity of selenium compounds, with special reference to the selenium problem. Chem Rev 1941;28:179-213.
28. Seko Y, Imura N. Active oxygen generation as a possible mechanism of selenium toxicity. Biomed Environ Sci 1997;10:333-9.
29. Vernie LN, De Vries M, Karreman L, Topp RJ, Bont WS. Inhibition of amino acid incorporation in a cell-free system and inhibition of protein synthesis in cultured cells by reaction products of selenite and thiols. Biochim Biophys Acta 1983;739:1-7.
30. Batist G, Katki AG, Klecker RW Jr., Myers CE. Selenium-induced cytotoxicity of human leukemia cells: interaction with reduced glutathione. Cancer Res 1986;46:5482-5.
31. Olm E, Fernandes AP, Hebert C, Rundlöf AK, Larsen EH, Danielsson O et al. Extracellular thiol-assisted selenium uptake dependent on the x(c)- cystine transporter explains the cancer-specific cytotoxicity of selenite. Proc Natl Acad Sci USA 2009;106:11400-5.
32. Bannai S, Sato H, Ishii T, Sugita Y. Induction of cystine transport activity in human fibroblasts by oxygen. J Biol Chem 1989;264:18480-4.
33. Banjac A, Perisic T, Sato H, Seiler A, Bannai S, Weiss N et al. The cystine/cysteine cycle: a redox cycle regulating susceptibility versus resistance to cell death. Oncogene 2007;27:1618-28.
34. Husbeck B, Nonn L, Peehl DM, Knox SJ. Tumor-selective killing by selenite in patient-matched pairs of normal and malignant prostate cells. Prostate 2006;66:218-25.
35. Spallholz JE, Palace VP, Reid TW. Methioninase and selenomethionine but not Se-methylselenocysteine generate methylselenol and superoxide in an in vitro chemiluminescent assay: implications for the nutritional carcinostatic activity of selenoamino acids. Biochem Pharmacol 2004;67:547-54.
36. Lee JT, Lee TJ, Park JW, Kwon TK. Se-methylselenocysteine sensitized TRAIL-mediated apoptosis via down-regulation of Bcl-2 expression. Int J Oncol 2009;34:1455-60.
37. Huang F, Nie C, Yang Y, Yue W, Ren Y, Shang Y et al. Selenite induces redox-dependent Bax activation and apoptosis in colorectal cancer cells. Free Radical Biol Med 2009;46:1186-96.
38. Suzuki M, Endo M, Shinohara F, Echigo S, Rikiishi H. Differential apoptotic response of human cancer cells to organoselenium compounds. Cancer Chemother Pharmacol 2010;66:475-84.
39. Snyder RD. Role of active oxygen species in metal-induced DNA strand breakage in human diploid fibroblasts. Mutat Res 1988;193:237-46.
40. Ghose A, Fleming J, El-Bayoumy K, Harrison PR. Enhanced sensitivity of human oral carcinomas to induction of apoptosis by selenium compounds: involvement of mitogen-activated protein kinase and Fas pathways. Cancer Res 2001;61:7479-87.
41. Wang Z, Jiang C, Ganther H, Lü J. Antimitogenic and proapoptotic activities of methylseleninic acid in vascular endothelial cells and associated effects on PI3K-AKT, ERK, JNK and p38 MAPK signaling. Cancer Res 2001;61:7171-8.
42. Lu J, Jiang C, Kaeck M, Ganther H, Vadhanavikit S, Clement IP et al. Dissociation of the genotoxic and growth inhibitory effects of selenium. Biochem Pharmacol 1995;50:213-9.
43. Jiang C, Wang Z, Ganther H, Lü J. Distinct effects of methylseleninic acid versus selenite on apoptosis, cell cycle, and protein kinase pathways in DU145 human prostate cancer cells 1 supported by grants from the department of defense (to J. L.). 1. Mol Cancer Ther 2002;1:1059-66.
44. Kim CY, Kim G-N, Wiacek JL, Chen C-Y, Kim K-H. Selenate inhibits adipogenesis through induction of transforming growth factor-β1 (TGF-β1) signaling. Biochem Biophys Res Commun 2012;426:551-7.
45. Kroemer G, Galluzzi L, Vandenabeele P, Abrams J, Alnemri ES, Baehrecke EH et al. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ 2009;16:3-11.
46. Galluzzi L, Vitale I, Abrams JM, Alnemri ES, Baehrecke EH, Blagosklonny MV et al. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ 2012;19:107-20.
47. Nilsonne G, Sun X, Nyström C, Rundlöf A-K, Potamitou Fernandes A, Björnstedt M et al. Selenite induces apoptosis in sarcomatoid malignant mesothelioma cells through oxidative stress. Free Radic Biol Med 2006;41:874-85.
48. Rudolf E, Rudolf K, Cervinka M. Selenium activates p53 and p38 pathways and induces caspase-independent cell death in cervical cancer cells. Cell Biol Toxicol 2008;24:123-41.
49. Ren Y, Huang F, Liu Y, Yang Y, Jiang Q, Xu C. Autophagy inhibition through PI3K/Akt increases apoptosis by sodium selenite in NB4 cells. BMB Rep 2009;42:599-604.
50. Kim EH, Sohn S, Kwon HJ, Kim SU, Kim MJ, Lee SJ et al. Sodium selenite induces superoxide-mediated mitochondrial damage and subsequent autophagic cell death in malignant glioma cells. Cancer Res 2007;67:6314-24.
51. Wallenberg M, Misra S, Wasik AM, Marzano C, Björnstedt M, Gandin V et al. Selenium induces a multi-targeted cell death process in addition to ROS formation. J Cell Mol Med, 2014. doi: 10.1111/jcmm.12214 (in press).
52. Chen T, Wong Y-S. Selenocystine induces s-phase arrest and apoptosis in human breast adenocarcinoma MCF-7 cells by modulating ERK and Akt phosphorylation. J Agric Food Chem 2008;56:10574-81.
53. Suzuki M, Endo M, Shinohara F, Echigo S, Rikiishi H. Rapamycin suppresses ROS-dependent apoptosis caused by selenomethionine in A549 lung carcinoma cells. Cancer Chemother Pharmacol 2011;67:1129-36.
54. Schröder M, Kaufman RJ. ER stress and the unfolded protein response. Mutat Res 2005;569:29-63.
55. Wu Y, Zhang H, Dong Y, Park Y-M, Ip C. Endoplasmic reticulum stress signal mediators are targets of selenium action. Cancer Res 2005;65:9073-9.
56. Guan L, Han B, Li J, Li Z, Huang F, Yang Y et al. Exposure of human leukemia NB4 cells to increasing concentrations of selenite switches the signaling from pro-survival to pro-apoptosis. Ann Hematol 2009;88:733-42.
57. Shchedrina VA, Zhang Y, Labunskyy VM, Hatfield DL, Gladyshev VN. Structure-function relations, physiological roles, and evolution of mammalian ER-resident selenoproteins. Antioxid Redox Signal 2010;12:839-49.
58. Shchedrina VA, Everley RA, Zhang Y, Gygi SP, Hatfield DL, Gladyshev VN. Selenoprotein K binds multiprotein complexes and is involved in the regulation of endoplasmic reticulum homeostasis. J Biol Chem 2011;286:42937-48.
59. Liu J, Rozovsky S. Contribution of selenocysteine to the peroxidase activity of selenoprotein S. Biochemistry 2013;52:5514-6.
60. Li G-X, Hu H, Jiang C, Schuster T, Lü J. Differential involvement of reactive oxygen species in apoptosis induced by two classes of selenium compounds in human prostate cancer cells. Int J Cancer 2007;120:2034-43.
61. Charalabopoulos K, Kotsalos A, Batistatou A, Charalabopoulos A, Vezyraki P, Peschos D et al. Selenium in serum and neoplastic tissue in breast cancer: correlation with CEA. Br J Cancer 2006;95:674-6.
62. Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov 2009;8:579-91.
63. Hoefig CS, Renko K, Köhrle J, Birringer M, Schomburg L. Comparison of different selenocompounds with respect to nutritional value vs. toxicity using liver cells in culture. J Nutr Biochem 2011;22:945-55.
64. Tran PA, Sarin L, Hurt RH, Webster TJ. Differential effects of nanoselenium doping on healthy and cancerous osteoblasts in coculture on titanium. Int J Nanomedicine 2010;5:351-8.
65. Fico ME, Poirier KA, Watrach AM, Watrach MA, Milner JA. Differential effects of selenium on normal and neoplastic canine mammary cells. Cancer Res 1986;46:3384-8.
66. Wu M, Kang MM, Schoene NW, Cheng WH. Selenium compounds activate early barriers of tumorigenesis. J Biol Chem 2010;285:12055-62.
67. Bjorkhem-Bergman L, Jonsson K, Eriksson LC, Olsson JM, Lehmann S, Paul C et al. Drug-resistant human lung cancer cells are more sensitive to selenium cytotoxicity. Effects on thioredoxin reductase and glutathione reductase. Biochem Pharmacol 2002;63:1875-84.
68. Clayton CC, Baumann CA. Diet and azo dye tumors: effect of diet during a period when the dye is not fed. Cancer Res 1949;9:575-82.
69. Ip C. Factors influencing the anticarcinogenic efficacy of selenium in dimethylbenz[a]anthracene-induced mammary tumorigenesis in rats. Cancer Res 1981;41:2683-6.
70. Medina D, Shepherd FS. Selenium inhibition of the neoplastic transformation in preneoplastic mammary cell populations. Cancer Lett 1984;24:227-34.
71. Milner JA. Selenium and the transplantable tumor. J Agric Food Chem 1984;32:436-42.
72. Watson-Williams E. A preliminary note on the treatment of inoperable carcinoma with selenium. Br Med J 1919;2:463-4.
73. Watson-Williams E. Selenium in the Treatment of Cancer. Br Med J 1935;1:1143-4.
74. 75Se) as tumor-localizing agent in man. J Nucl Med 1966;7:197-208.
75. Weisberger AS, Suhrland LG. Studies on analogues of L-cysteine and L-cystine: III. The effect of selenium cystine on leukemia. Blood 1956;11:19-30.
76. Reid ME, Stratton MS, Lillico AJ, Fakih M, Natarajan R, Clark LC et al. A report of high-dose selenium supplementation: response and toxicities. J Trace Elem Med Biol 2004;18:69-74.